Benznidazole-Loaded Polymeric Nanoparticles for Oral Chemotherapeutic Treatment of Chagas Disease

Chagas disease (CD) is a worldwide public health problem. Benznidazole (BZ) is the drug used to treat it. However, in its commercial formulation, it has significant side effects and is less effective in the chronic phase of the infection. The development of particulate systems containing BZ is there...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2024-06, Vol.16 (6), p.800
Main Authors: Sousa, Lucas Resende Dutra, Duarte, Thays Helena Chaves, Xavier, Viviane Flores, das Mercês, Aline Coelho, Vieira, Gabriel Maia, Martins, Maximiliano Delany, Carneiro, Cláudia Martins, Dos Santos, Viviane Martins Rebello, Dos Santos, Orlando David Henrique, Vieira, Paula Melo de Abreu
Format: Article
Language:English
Subjects:
benznidazole
Chagas disease
Chemical properties
Chemotherapy
Diagnosis
Drug delivery systems
Drug therapy
formulations
Health aspects
Nanoparticles
Oral administration
Patients
Polyethylene glycol
polymeric nanoparticles
Polymers
Polyvinyl alcohol
Scanning electron microscopy
trypanocidal activity
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chagas disease (CD) is a worldwide public health problem. Benznidazole (BZ) is the drug used to treat it. However, in its commercial formulation, it has significant side effects and is less effective in the chronic phase of the infection. The development of particulate systems containing BZ is therefore being promoted. The objective of this investigation was to develop polymeric nanoparticles loaded with BZ and examine their trypanocidal impact in vitro. Two formulas (BNP1 and BNP2) were produced through double emulsification and freeze drying. Subsequent to physicochemical and morphological assessment, both formulations exhibited adequate yield, average particle diameter, and zeta potential for oral administration. Cell viability was assessed in H9C2 and RAW 264.7 cells in vitro, revealing no cytotoxicity in cardiomyocytes or detrimental effects in macrophages at specific concentrations. BNP1 and BNP2 enhanced the effect of BZ within 48 h using a treatment of 3.90 μg/mL. The formulations notably improved NO reduction, particularly BNP2. The findings imply that the compositions are suitable for preclinical research, underscoring their potential as substitutes for treating CD. This study aids the quest for new BZ formulations, which are essential in light of the disregard for the treatment of CD and the unfavorable effects associated with its commercial product.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics16060800